

10/056,298


-2-

A0000506-01-DRK

Amendments to the Claims:

1. (Cancelled)

2. (Currently Amended) A method for preventing or treating gastrointestinal disorders comprising administering to a patient in need of treatment an effective amount of a compound of formula I-IV:



or a pharmaceutically acceptable salt thereof, wherein n is an integer of from 1 to 4.

3. (Currently Amended) The method of Claim 1 or 2, wherein the compound is selected from:

- (1 $\alpha$ ,6 $\alpha$ ,8 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
- (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
- (1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid,
- (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
- (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
- (1 $\alpha$ ,5 $\beta$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
- (1 $\alpha$ ,6 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (1 $\alpha$ ,7 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
- (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
- (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,

10/056,298

-3-

A0000506-01-DRK

(1 $\alpha$ ,5 $\beta$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
(1 $\alpha$ ,6 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
(1 $\alpha$ ,7 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
(1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
(1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
(1 $\alpha$ ,6 $\alpha$ ,8 $\alpha$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
(1 $\alpha$ ,7 $\alpha$ ,9 $\alpha$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
(1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
(1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,  
(1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
(1 $\alpha$ ,6 $\alpha$ ,8 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
(1 $\alpha$ ,7 $\alpha$ ,9 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((3 $\alpha$ R,5R,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ R,5S,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5S,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5R,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((2R,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ S,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid.

10/056,298

-4-

A0000506-01-DRK

((2S,4 $\alpha$ S,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((2R,4 $\alpha$ R,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((3 $\alpha$ R,5R,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ R,5S,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5S,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5R,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((2R,4 $\alpha$ R,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ S,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ R,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid, and  
((2R,4 $\alpha$ S,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
or a pharmaceutically acceptable salt thereof.

3/4. (Currently Amended) The method according to Claim ~~1 or 2~~<sup>1</sup>, where n the compound is the compound of formula I or a pharmaceutically acceptable salt thereof.

5. (Cancelled)

10/056,298

-5-

A0000506-01-DRK

4/6. (Currently Amended) A method for ~~preventing or treating~~ gastrointestinal disorders comprising administering to a patient in need of treatment an effective amount of (1 $\alpha$ -3 $\alpha$ -5 $\alpha$ -)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid or a pharmaceutically acceptable salt thereof.

5/7. (Currently Amended) The method according to any one of Claims <sup>1, 2, 3</sup> ~~2, 3, 4~~ and <sup>4</sup> ~~1 to 6~~, wherein the disorder is functional bowel disorder or inflammatory bowel disease.

6/8. (Original) The method according to Claim <sup>5</sup> ~~7~~, wherein the functional bowel disorder is gastro-esophageal reflux, dyspepsia, irritable bowel syndrome or functional abdominal pain syndrome.

7/9. (Original) The method according to Claim <sup>5</sup> ~~7~~, wherein the inflammatory bowel disease is Crohn's disease, ileitis or ulcerative colitis.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)


14. (Cancelled)

8/15. (Previously Added) A method for treating irritable bowel syndrome comprising administering to a patient in need of treatment an effective amount of a compound of formula I-IV:

10/056,298

-6-

A0000506-01-DRK



or a pharmaceutically acceptable salt thereof, wherein n is an integer of from 1 to 4.

- 8
- 9 16. (Previously Added) The method of Claim 1<sup>8</sup>, wherein the compound I is selected from:
- (1 $\alpha$ ,6 $\alpha$ ,8 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
  - (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
  - (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
  - (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
  - (1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid,
  - (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
  - (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
  - (1 $\alpha$ ,5 $\beta$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
  - (1 $\alpha$ ,6 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
  - (1 $\alpha$ ,7 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
  - (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
  - (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
  - (1 $\alpha$ ,5 $\beta$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
  - (1 $\alpha$ ,6 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
  - (1 $\alpha$ ,7 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
  - (1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
  - (1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
  - (1 $\alpha$ ,6 $\alpha$ ,8 $\alpha$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
  - (1 $\alpha$ ,7 $\alpha$ ,9 $\alpha$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
  - (1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,

10/056,298

-7-

A0000506-01-DRK

(1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,  
(1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
(1 $\alpha$ ,6 $\alpha$ ,8 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
(1 $\alpha$ ,7 $\alpha$ ,9 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((3 $\alpha$ R,5R,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid  
((3 $\alpha$ R,5S,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5S,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5R,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((2R,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ S,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,  
((2R,4 $\alpha$ R,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,  
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,

DRK A506 US Response 1-16-2004

10/056,298

-8-

A0000506-01-DRK

((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((3 $\alpha$ R,5R,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ R,5S,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5S,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5R,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((2R,4 $\alpha$ R,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ S,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ R,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid, and  
((2R,4 $\alpha$ S,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,  
or a pharmaceutically acceptable salt thereof.

10/17.

(Previously Added) The method according to Claim <sup>8</sup>15, wherein the compound is the compound of formula I or a pharmaceutically acceptable salt thereof.

11/18.

(Currently Amended) A method for treating irritable bowel syndrome comprising administering to a patient in need of treatment an effective amount of (1 $\alpha$ -, 3 $\alpha$ -, 5 $\alpha$ -)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid or a pharmaceutically acceptable salt thereof.

19.

(Previously Added) A pharmaceutical composition for the treatment of irritable bowel syndrome of comprising a compound of formula I-IV.

20.

(Currently Amended) The pharmaceutical composition according to claim 19 comprising (1 $\alpha$ -, 3 $\alpha$ -, 5 $\alpha$ -)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid.